SEC Form 4 · accession 0001123292-18-001091
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Murray
Director
Period of report
Nov 28, 2018
Accepted (ET)
Nov 30, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Nov 28, 2018 | M | 25,000 | $1.35 | A | 341,396 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.35 | Nov 28, 2018 | M | 25,000 | D | — | Dec 8, 2018 | Common Shares | 25,000 | 0 | D |
Explanation of responses
- F1Converted from an exercise price of C$1.80 based on a conversion rate of C$1.33:$1.00 as of November 28, 2018.
- F2The option vested 1/4 on December 8, 2008, with the remaining portion vesting in equal annual installments beginning on December 8, 2009.